Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Company Description (as filed with the SEC)
We develop tiny, sustained-release products designed to deliver drugs and biologics at a controlled and steady rate for weeks, months or years. Our strategy is to use our Durasert™ and Tethadur™ drug delivery technologies to independently develop products that deliver proven drugs and biologics, while continuing to leverage these technologies through collaboration and license agreements. We are focused on treatment of chronic diseases of the back of the eye and are also exploring applications outside ophthalmology. Our lead product candidate Medidur™ is in a pivotal Phase III clinical trial, our lead licensed product ILUVIEN® has been approved in the European Union (EU) and is pending approval with the U.S. Food and Drug Administration (FDA), and our pipeline includes potential product candidates at earlier stages of development. ... More ...